ACKR2 | Atypical chemokine receptor 2 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enriched |
ADRB1 | Adrenoceptor beta 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
AGTR1 | Angiotensin II receptor, type 1 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Group enriched |
CASR | Calcium-sensing receptor | Disease related genes FDA approved drug targets G-protein coupled receptors Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CCR6 | Chemokine (C-C motif) receptor 6 | CD markers G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
CCR7 | Chemokine (C-C motif) receptor 7 | Cancer-related genes CD markers G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
CD97 | CD97 molecule | CD markers G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Expressed in all |
CHRM1 | Cholinergic receptor, muscarinic 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
CXCR2 | Chemokine (C-X-C motif) receptor 2 | Cancer-related genes CD markers G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CXCR3 | Chemokine (C-X-C motif) receptor 3 | CD markers G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
CXCR5 | Chemokine (C-X-C motif) receptor 5 | CD markers G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
DRD5 | Dopamine receptor D5 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
EDNRA | Endothelin receptor type A | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
ELTD1 | EGF, latrophilin and seven transmembrane domain containing 1 | G-protein coupled receptors Plasma proteins Predicted membrane proteins Transporters
| | | | | Mixed |
GABBR2 | Gamma-aminobutyric acid (GABA) B receptor, 2 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enriched |
GLP2R | Glucagon-like peptide 2 receptor | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
GPR113 | G protein-coupled receptor 113 | G-protein coupled receptors Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
GPR123 | G protein-coupled receptor 123 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
GPR132 | G protein-coupled receptor 132 | G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins
| | | | | Mixed |
GPR135 | G protein-coupled receptor 135 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
GPR160 | G protein-coupled receptor 160 | G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins
| | | | | Mixed |
GPR162 | G protein-coupled receptor 162 | G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
GPR182 | G protein-coupled receptor 182 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enriched |
GPR37L1 | G protein-coupled receptor 37 like 1 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enriched |
GPR61 | G protein-coupled receptor 61 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
HCRTR2 | Hypocretin (orexin) receptor 2 | G-protein coupled receptors Predicted membrane proteins
| | | | | Not detected |
HTR2A | 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enriched |
NPSR1 | Neuropeptide S receptor 1 | Disease related genes G-protein coupled receptors Potential drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
OPRM1 | Opioid receptor, mu 1 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
P2RY12 | Purinergic receptor P2Y, G-protein coupled, 12 | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
P2RY13 | Purinergic receptor P2Y, G-protein coupled, 13 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
SERINC5 | Serine incorporator 5 | Predicted membrane proteins
| | | | | Expressed in all |
SPPL2A | Signal peptide peptidase like 2A | Enzymes Plasma proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
TM9SF1 | Transmembrane 9 superfamily member 1 | Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
TM9SF2 | Transmembrane 9 superfamily member 2 | Predicted membrane proteins Transporters
| | | | | Expressed in all |
TMC5 | Transmembrane channel-like 5 | Predicted membrane proteins
| | | | | Tissue enhanced |